GSK of­fers glimpse at pos­i­tive Phase 3 an­tibi­ot­ic da­ta for uro­gen­i­tal gon­or­rhea

Two months af­ter its uro­gen­i­tal gon­or­rhea an­tibi­ot­ic hit the pri­ma­ry end­point in a reg­is­tra­tional tri­al, GSK is pro­vid­ing a clos­er look at re­sults as it gears up for reg­u­la­to­ry fil­ings in 2025.

The Phase 3 EA­GLE-1 tri­al com­pared GSK’s an­tibi­ot­ic with stan­dard-of-care cef­tri­ax­one plus azithromycin in 600 peo­ple with un­com­pli­cat­ed uro­gen­i­tal gon­or­rhea. In the pri­ma­ry end­point of mi­cro­bi­o­log­i­cal re­sponse at the test-of-cure vis­it three to sev­en days af­ter treat­ment, gepoti­dacin achieved a 92.6% suc­cess rate ver­sus 91.2% for con­trol, per a Wednes­day re­lease. The p-val­ue of the non-in­fe­ri­or­i­ty end­point was not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER